Search

The aim of the present study was to investigate the association between the dynamic intensity-modulated radiation therapy planned γ analysis passing rate and respiratory amplitude (A) and period (T) for different tumor volumes. A total of 30 patients with malignant lung tumors were divided into three groups: A; B; and C. The average tumor volumes (V) in the A, B and C groups were 635, 402 and 213 cm3, respectively. The simulated A values were set at 0, 5, 10, 15, 20 and 25 mm. The T values were set at 4, 5 and 6 sec. The γ analysis passing rate was calculated under different conditions (dose difference, 3%; distance difference, 3 mm). Compared with the γ analysis passing rate in the A group (A=0, static; T=4, 5, 6 sec), the γ analysis passing rate deviation (A=5 mm) was 0.05). With a gradual increase in A value, the passing rate decreased. The deviation between the 3 groups was

Dose distribution was calculated and analyzed on the basis of 16-bit computed tomography (CT) images in order to investigate the effect of scanning conditions on CT for metal implants. Stainless steel and titanium rods were inserted into a phantom, and CT images were obtained by scanning the phantom under various scanning conditions: i) Fixed tube current of 230 mA and tube voltages of 100, 120, and 140 kV; and ii) fixed tube voltage of 120 kV and tube currents of 180, 230, and 280 mA. The CT value of the metal rod was examined and corrected. In a Varian treatment planning system, a treatment plan was designed on the basis of the CT images obtained under the set scanning conditions. The dose distributions in the phantom were then calculated and compared. The CT value of the metal area slightly changed upon tube current alteration. The dose distribution in the phantom was also similar. The maximum CT values of the stainless steel rod were 14,568, 14,127 and 13,295 HU when the tube voltages were modified to 100, 120, and 140 kV, respectively. The corresponding CT values of the titanium rod were 9,420, 8,140 and 7,310 HU. The dose distribution of the radiotherapy plan changed significantly as the tube voltage varied. Compared with the reference dose, the respective maximum dose differences of the stainless steel and titanium rods in the phantom were 5.70, and 6.62% when the tube voltage varied. The changes in tube currents resulted in a maximum dose error of

It is well established that transcriptional silencing of critical tumor suppressor genes by DNA methylation is a fundamental process in the initiation of lung cancer. However, the involvement of microRNAs (miRNAs) in restoring abnormal DNA methylation patterns in lung cancer is not well understood. Therefore, and since miRNA-101 is complementary to the 3'-untranslated region of DNA methyltransferase 3A (DNMT3A), we investigated whether miRNA-101 could restore normal DNA methylation patterns in lung cancer cell lines. Bioinformatics has indicated that DNMT3A is a major target of miR-101. In addition, the overexpression of miR-101 downregulates DNMT3A. Using a methylation-specific polymerase chain reaction assay, we demonstrated that methylation of the phosphatase and tensin homolog (PTEN) promoter was reduced in A549 cells transfected with miR-101, but not in the transfected control. Furthermore, overexpression of miR-101 and silencing of DNMT3A suppressed lung cell proliferation and S/G2 transition, and increased apoptosis through the PTEN/AKT pathway in vitro. Furthermore, we observed the opposite phenomenon in A549 cells transfected with a miR-101 inhibitor. Subsequent investigation revealed that overexpression of miR-101 significantly inhibited the tumorigenicity of A549 cells in a nude mouse xenograft model. These results demonstrate that miR-101 affects lung cancer progression through the PTEN/AKT signaling pathway by targeting DNMT3A in lung cells, suggesting that miR-101 may be a novel potential therapeutic strategy in lung cancer treatment.